Biomarkers as risk factors for outcomes
| . | Univariate analysis . | Adjusted analysis* . | ||
|---|---|---|---|---|
| Outcome/cytokine panel . | OR or HR (95% CI) . | P . | OR or HR (95% CI) . | P . |
| Day 28 nonresponse | ||||
| High ST2 | 2.63 (1.36-5.06) | .004 | 1.37 (0.63-2.98) | .43 |
| High panel 2 | 1.84 (1.01-3.37) | .048 | 1.07 (0.52-2.18) | .86 |
| High panel 3 | 2.94 (1.52-5.67) | .001 | 1.28 (0.57-2.86) | .55 |
| High panel 4 | 3.68 (1.90-7.14) | <.001 | 2.03 (0.94-4.35) | .070 |
| High panel 6 | 2.63 (1.44-4.80) | .002 | 1.39 (0.69-2.81) | .36 |
| Day 180 survival | ||||
| High ST2 | 3.89 (2.14-7.08) | <.001 | 2.12 (1.13-3.99) | .019 |
| High panel 2 | 4.00 (2.14-7.50) | <.001 | 2.65 (1.39-5.06) | .003 |
| High panel 3 | 4.07 (2.23-7.40) | <.001 | 1.92 (1.00-3.68) | .050 |
| High panel 4 | 4.02 (2.21-7.31) | <.001 | 2.16 (1.14-4.07) | .017 |
| High panel 6 | 3.92 (2.04-7.52) | <.001 | 2.30 (1.16-4.55) | .017 |
| Day 180 nonrelapse mortality | ||||
| High ST2 | 5.16 (2.54-10.4) | <.001 | 2.43 (1.17-5.09) | .018 |
| High panel 2 | 4.50 (2.13-9.51) | <.001 | 2.68 (1.25-5.77) | .011 |
| High panel 3 | 6.07 (2.96-12.4) | <.001 | 2.45 (1.14-5.28) | .022 |
| High panel 4 | 5.25 (2.59-10.6) | <.001 | 2.53 (1.21-5.28) | .014 |
| High panel 6 | 6.92 (2.85-16.8) | <.001 | 3.61 (1.44-9.03) | .006 |
| . | Univariate analysis . | Adjusted analysis* . | ||
|---|---|---|---|---|
| Outcome/cytokine panel . | OR or HR (95% CI) . | P . | OR or HR (95% CI) . | P . |
| Day 28 nonresponse | ||||
| High ST2 | 2.63 (1.36-5.06) | .004 | 1.37 (0.63-2.98) | .43 |
| High panel 2 | 1.84 (1.01-3.37) | .048 | 1.07 (0.52-2.18) | .86 |
| High panel 3 | 2.94 (1.52-5.67) | .001 | 1.28 (0.57-2.86) | .55 |
| High panel 4 | 3.68 (1.90-7.14) | <.001 | 2.03 (0.94-4.35) | .070 |
| High panel 6 | 2.63 (1.44-4.80) | .002 | 1.39 (0.69-2.81) | .36 |
| Day 180 survival | ||||
| High ST2 | 3.89 (2.14-7.08) | <.001 | 2.12 (1.13-3.99) | .019 |
| High panel 2 | 4.00 (2.14-7.50) | <.001 | 2.65 (1.39-5.06) | .003 |
| High panel 3 | 4.07 (2.23-7.40) | <.001 | 1.92 (1.00-3.68) | .050 |
| High panel 4 | 4.02 (2.21-7.31) | <.001 | 2.16 (1.14-4.07) | .017 |
| High panel 6 | 3.92 (2.04-7.52) | <.001 | 2.30 (1.16-4.55) | .017 |
| Day 180 nonrelapse mortality | ||||
| High ST2 | 5.16 (2.54-10.4) | <.001 | 2.43 (1.17-5.09) | .018 |
| High panel 2 | 4.50 (2.13-9.51) | <.001 | 2.68 (1.25-5.77) | .011 |
| High panel 3 | 6.07 (2.96-12.4) | <.001 | 2.45 (1.14-5.28) | .022 |
| High panel 4 | 5.25 (2.59-10.6) | <.001 | 2.53 (1.21-5.28) | .014 |
| High panel 6 | 6.92 (2.85-16.8) | <.001 | 3.61 (1.44-9.03) | .006 |
Adjusted on a simple clinical model where high-risk patients are those with initial liver GVHD or those aged 50 years or more with initial GVHD grade 3.